By selling its Wako chemicals unit, the top Japanese drugmaker Takeda could raise $1 billion for reinvestment in its pipeline.

Rumors of Merck brand sale in India raise questions about the future of its generic drug division.

Sanofi provided insight into the logistics hurdles faced by vaccine makers in China after a distribution and sales rule changed.

China's Shanghai Fosun Pharmaceuticals has reportedly won a bidding war for India's privately held injectable maker Gland Pharma in a rare cross-…

China Resources has teamed up with Australian investment bank Macquarie to buy a majority of cancer and cardio medical care provider GenesisCare in a $1.3…

China’s Jilin Zixin Pharmaceutical Industrial has splashed out $42 million to buy a Rhode Island-based high-definition genome mapping company, Nabsys 2.0.

Osaka-based Takeda Pharmaceutical is reviewing prospects to sell a majority stake in Wako Pure Chemical.

Management has offered to buy Beijing-based radiotherapy and diagnostic firm Concord Medical Services in a $228 million bid.

Hanmi Pharmaceutical eyes branded drugs, fast-paced R&D and investment in China to get growth on track.

M&A